BioSpace News Archive

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors and tumor metastases, today announced it will report financial results for its second fiscal quarter ended September 30, 2020

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated randomized Phase II clinical trial evaluating its lead product candidate eftilagimod alpha (“efti” or “IMP321”) in hospitalized patients with COVID-19

Taiho Oncology, Inc., today announced the launch of its World of Hope campaign to support patients living with myelodysplastic syndrome (MDS) and bring much-needed attention to this rare and difficult-to-treat cancer during MDS World Awareness Day on October 25, 2020 . MDS is a rare blood cancer that impacts approximately 4 to 5

- Lianluo Smart Limited (“LLIT” or the “Company”) (NASDAQ: LLIT), a China based professional smart service and products provider, today announced that the Company has effected a one-for-eight (1-for-8) reverse stock split of Class A common shares, par value $0.002731 per share, and Class B common shares, par value $0.002731 per share,

Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020, before the market opens.

Eucrates Biomedical Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 10,000,000 units at an initial public offering price of $10.00 per unit.

Remote Medical International, the company providing workplace health and safety services for Fortune 100 corporations, today announced it has partnered with 1health.io, the leading testing as a service (TaaS) company, to deliver saliva-based COVID-19 tests to its customers working in isolated work sites across the country

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate.

Finerenone is a potential first-in-class investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that works on the pathway of MR overactivation, a key contributor to disease progression in patients with chronic kidney disease and type 2 diabetes FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease and type 2 diabetes with a primary composite endpoint exclusively cons

FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause Results reinforce FARXIGA’s potential to treat a wide range of patients with chronic kidney disease WILMINGTON, Del.--( BUSINESS WIRE )-- A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s FARXIGA ® (dapagliflozin), on